Market Newsdesk

REDWOOD CITY, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it has completed required lab testing and is completing its 510(k) FDA filing for its latest potential product offering, Biotres. Biotres is a 3-lead patch product for ECG and arrhythmia monitoring for patients at risk for or being diagnosed with certain cardiac issues. Biotres can work as a Holter, Event Loop, and Extended Holter. The company expects to file in the fourth quarter of 2020.

“Biotres is a natural extension of our cardiac diagnostic offering with Bioflux. For lower risk patients, a comfortable, easy to wear, holter product for long term monitoring.”, stated Waqaas Al Siddiq, CEO of Biotricity. Some of our existing customers have requested a product like this previously and we believe we will experience great adoption with Biotres. The Biotres is tailor made for the $4 Billion-dollar holter market.”

The Biotres is a holter product that was developed to address the challenges that exist with current holter patch products. The Biotres is designed with the following key features:

• 3 Channel Recording – A wearable holter patch device that can provide continuous 3 channel recording of ECG (heart) data. All other holter patch devices are 1 channel or 2 channels.
• Rechargeable
  Battery– The device can be worn continuously for 48 hours, before needing to be charged for 1 hr., enabling continuous data collection for extended periods of time without any intervention, something not possible with current holter patch solutions.
• Wireless Connectivity
  – The unique device utilizes Bluetooth technology to offload data, reducing the time for diagnoses. Current holter patch solutions can take up to a week before diagnoses are available due to manual data downloading and a lack of connectivity.
• User-Friendly Design – Easy to understand and comfortable to wear during regular day-to-day activities.

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic products for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts:
Donna Loughlin Michaels
LMGPR
408.393.5575
[email protected]

Investor Relations:
Biotricity Inc.
1-800-590-4155
[email protected]

ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in Adults


ZILXI 
demonstrated a favorable safety and tolerability profile for up to 52 weeks of treatment


Efficacy of ZILXI continued to develop for an additional 40 weeks of treatment after an initial treatment period of 12 weeks

BRIDGEWATER, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) announced today the peer reviewed publication of long-term safety and efficacy data for ZILXI™ (minocycline) topical foam, 1.5% in the Journal of Clinical and Aesthetic Dermatology (JCAD). Study FX2016-13 evaluated the safety and efficacy of ZILXI for up to 40 weeks of open-label treatment immediately following an initial 12-week double-blind treatment. This study was conducted by VYNE to support the New Drug Application (NDA) of ZILXI which was approved by the U.S. Food and Drug Administration (FDA) for the treatment of inflammatory lesions of rosacea in adults in May of this year.

“Following the commercial launch of ZILXI in October, we are pleased that JCAD has accepted these long-term safety and efficacy data for publication,” said David Domzalski, CEO of VYNE. “We hope that ZILXI’s safety profile for long term treatment coupled with enduring efficacy will provide patients living with rosacea an attractive new option for lasting control of their disease.”  

Highlights from the Long-Term Safety & Efficacy
in Study FX2016-13
:

Study FX2016-13 included a total of 504 patients in the all-treated population, all of whom had completed 12 weeks of ZILXI or vehicle treatment in one of two preceding double-blind phase 3 studies (Studies FX2016-11 or FX2016-12). Patients continued for up to an additional 40 weeks of open-label treatment with ZILXI.

410 patients completed participation in the study of which 332 patients had received a total of 52 weeks of ZILXI therapy which was in excess of the subject sample size requirements specified in the regulatory guidance for this type of safety evaluation (ICH E1A, 1995). 96.1% of patients participating in study FX2016-13 received a minimum of 26 weeks of ZILXI therapy. Key findings from the study are as follows:

• Non-dermal adverse events were comparable in type and frequency with those reported during the preceding 12-week double-blind studies. The most frequently reported treatment-emergent adverse event in this study was upper respiratory tract infection (common cold) (14 subjects). A total of 5 patients discontinued the study over the course of 40 weeks of treatment due to an adverse event and no serious drug-related adverse events were reported.
• In the assessment of facial dermal tolerability at Week 52, the majority of subjects (>57%) had no signs of burning/stinging, flushing/blushing, dryness/xerosis, itching, peeling/desquamation, or post-inflammatory hyperpigmentation. All facial local tolerability assessments made at Week 52 improved relative to assessments made at the study baseline of the preceding double-blind studies. In this regard, the percentage of patients with clear and almost clear erythema at study baseline of the preceding double-blind studies improved from 4.0% to 59.3% by the end of the open-label study.
• Long-term treatment with ZILXI was associated with a progressive decrease in inflammatory lesions and a parallel increase in the proportion of subjects achieving IGA treatment success. The overall mean percent change (reduction) from study baseline of the preceding double-blind studies when assessed at Week 52 was 82.3%. Equally, the proportion of subjects achieving Investigator Global Assessment (IGA) treatment success (IGA score of 0 “clear” or 1 “almost clear”) at week 52 was 79.8%.
• Subject satisfaction with ZILXI treatment continued to increase when re-assessed at Week 52 relative to Week 12 assessments made in the preceding double-blind studies. At Week 52, the majority of subjects (82.4%) reported being overall “satisfied” or “very satisfied” with ZILXI in treating their rosacea. The majority of subjects (83.2%) were also satisfied or very satisfied with how ZILXI compared with other products, as well as with its ease of use (92.9%). Most subjects (83.2%) reported being “likely” or “very likely” to recommend ZILXI to a friend.

“We are pleased that our comprehensive long-term safety and efficacy evaluation of ZILXI has been published in JCAD. ZILXI is well tolerated, with an acceptable safety profile and impressive long-term efficacy which are important factors in the treatment of chronic, relapsing dermatological conditions such as rosacea,” said Dr. Iain Stuart, Chief Scientific Officer of VYNE.

Indication

ZILXI (minocycline) topical foam, 1.5% is a topical form of the antibiotic minocycline for the treatment of adults with pimples and bumps caused by a condition called rosacea. ZILXI is available by prescription only.

ZILXI should not be used for the treatment of infections. It is not known if ZILXI is safe and effective in children. ZILXI is for use on skin only (topical use). ZILXI is not for use in the mouth, eyes or vagina.

Important Safety Information

• ZILXI should not be used in people who are allergic to ZILXI or any tetracycline medicine. Use of ZILXI should be stopped right away if a rash or other allergic symptom occurs.
• ZILXI should not be used in women who are pregnant, may become pregnant or are nursing. If a woman becomes pregnant while using ZILXI, she should talk to her doctor. Tetracycline medicine when taken by mouth during pregnancy, infancy and/or childhood up to the age of 8 years may permanently discolor teeth (yellow-gray-brown) and may slow the growth of bones.
• ZILXI is flammable and fire, flame, and smoking must be avoided when applying and right after applying ZILXI.
• People should protect their skin from the sun while using ZILXI and avoid sunlight or artificial sunlight such as sunlamps or tanning beds. Use of ZILXI should be stopped if skin is sunburned.
• When taken by mouth, minocycline may cause feelings of lightheadedness, dizziness or spinning. People should not drive or operate dangerous machinery if they have these symptoms.

ZILXI is a topical foam that contains minocycline, a tetracycline medicine. It should not be taken by mouth. However, tetracyclines, when taken by mouth (capsules or tablets), may cause serious side effects, including: diarrhea, which may be caused by an infection and can cause watery or bloody stools; loss of appetite; tiredness; yellowing of the skin or eyes (jaundice); bleeding more easily than normal; confusion; sleepiness; vision changes, including blurred vision, double vision, or permanent vision loss; unusual headaches; fever; rash; joint pain; body weakness; discoloration or darkening of the skin, scars, teeth, or gums. People should call their doctor right away if these side effects occur.

The most common side effect of ZILXI is diarrhea.

These are not all of the possible side effects for ZILXI. People should contact their doctor for medical advice about side effects and be sure to tell their doctor about all of their medical conditions and medicines they take before using ZILXI.

People are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information for ZILXI.

About Rosacea

Rosacea is a diverse skin condition that most commonly presents with symptoms such as deep facial redness, spider veins (telangiectasia) and acne-like inflammatory lesions (papules and pustules). It can create psychosocial burdens, such as embarrassment, anxiety and low self-esteem that can adversely affect quality of life.¹ Rosacea is most frequently seen in adults between 30 and 50 years of age. It affects more than 16 million people in the United States; up to 28% of these sufferers have rosacea with inflammatory lesions.²

About VYNE Therapeutics Inc.

VYNE Therapeutics’ mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.

With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for AMZEEQ^® (minocycline) topical foam, 4%, the world’s first topical minocycline, and for ZILXI™ (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. For more information about our approved products, please see AMZEEQ’s Full Prescribing Information at amzeeq.com and ZILXI’s Full Prescribing Information at zilxi.com.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www. vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Media Relations:
Bridgette Potratz
Zeno Group
312-358-2950
[email protected]

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
646-889-1200
[email protected]

Andrew Saik
Chief Financial Officer
VYNE Therapeutics
908-731-6180
[email protected]

Cautionary Statement Regarding Forward-Looking Statements

This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the development and commercialization of VYNE’s products and product candidates and other statements regarding the future expectations, plans and prospects of VYNE. All statements in this press release which are not historical facts are forward-looking statements. Any forward-looking statements are based on VYNE’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the COVID-19 pandemic and its impact on our business operations; adverse events associated with the commercialization of AMZEEQ and ZILXI; the outcome and cost of clinical trials for current and future product candidates; determination by the FDA that results from VYNE’s clinical trials are not sufficient to support registration or marketing approval of product candidates; the outcome of pricing, coverage and reimbursement negotiations with third party payors for AMZEEQ, ZILXI or any other products or product candidates that VYNE may commercialize in the future; whether, and to what extent, third party payors impose additional requirements before approving AMZEEQ and ZILXI prescription reimbursement; the eligible patient base and commercial potential of AMZEEQ, ZILXI or any of VYNE’s other products or product candidates; risks that VYNE’s intellectual property rights, such as patents, may fail to provide adequate protection, may be challenged and one or more claims may be revoked or interpreted narrowly or will not be infringed; risks that any of VYNE’s patents may be held to be narrowed, invalid or unenforceable or one or more of VYNE’s patent applications may not be granted and potential competitors may also seek to design around VYNE’s granted patents or patent applications; additional competition in the acne and dermatology markets; risks related to our indebtedness; inability to raise additional capital on favorable terms or at all; VYNE’s ability to recruit and retain key employees; and VYNE’s ability to stay in compliance with applicable laws, rules and regulations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause VYNE’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in VYNE’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, as well as discussions of potential risks, uncertainties, and other important factors in VYNE’s subsequent filings with the U.S. Securities and Exchange Commission. Although VYNE believes these forward-looking statements are reasonable, they speak only as of the date of this announcement and VYNE undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events.

1. Aksoy, B., Altaykan‐Hapa, A., Egemen, D., Karagöz, F. and Atakan, N. (2010), The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. British Journal of Dermatology, 163: 719-725.
2. Gether et al. Incidence and prevalence of rosacea: a systematic review and meta-analysis. British Journal of Dermatology 25 Feb 2018.179: 282-289.

WORCESTER, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it will host a key opinion leader (KOL) call on MB-106 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma on Wednesday, December 9, 2020, at 1:00 p.m. EST.

The call will feature presentations by KOLs Mazyar Shadman, M.D., M.P.H., Fred Hutchinson Cancer Research Center (“Fred Hutch”), and Brian Till, M.D., Fred Hutch, who will discuss the interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma that the company is developing in collaboration with Fred Hutch. Data from this study have been selected for a poster presentation at the 62^nd American Society of Hematology Annual Meeting.

During the call, Drs. Shadman and Till will also discuss the modified cell manufacturing process that was co-developed by Fred Hutch and Mustang Bio, as well as the correlative science observed in the study to date. The Mustang team will then give a corporate update on its pipeline and future plans. Following the formal presentations, the Mustang team, along with Drs. Till and Shadman, will be available for questions.

To register for the call, please click here.

About Dr.
Shadman

Mazyar Shadman, M.D., M.P.H., is an associate professor at the University of Washington (UW) and Fred Hutch. He is a hematologic malignancies expert who specializes in treating patients with lymphoma / chronic lymphocytic leukemia (CLL). He is involved in clinical trials using novel therapeutic agents, immunotherapy (CAR T cell), and stem cell transplant for treatment of lymphoid malignancies with a focus on CLL. He also studies the clinical outcomes of patients using institutional and collaborative retrospective cohort studies. Dr. Shadman received his M.D. from Tehran University in Iran. He finished internal medicine internship and residency training at the Cleveland Clinic in Cleveland, Ohio. He completed his training in hematology and medical oncology fellowships at UW and Fred Hutch. Dr. Shadman also earned an M.P.H. degree from UW and was a fellow for National Cancer Institute’s cancer research training program at Fred Hutch, where he studies cancer epidemiology.

About Dr. Till

Brian Till, M.D., is an Associate Professor in the Clinical Research Division of Fred Hutch and Department of Medicine at UW. His laboratory focuses on developing chimeric antigen receptor (CAR)-based immunotherapies for non-Hodgkin lymphoma and understanding why CAR T cell therapies work for some patients but not for others. He led the first published clinical trial testing CAR T cells as a treatment for lymphoma patients. Dr. Till also has a clinical practice treating patients with lymphoma and attends on the stem cell transplantation and immunotherapy services at the Seattle Cancer Care Alliance.

About Mustang Bio

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for X-linked severe combined immunodeficiency (XSCID), also known as bubble boy disease. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.mustangbio.com.

Forward‐Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contacts:

Jaclyn Jaffe and William Begien
Mustang Bio, Inc.
(781) 652-4500
[email protected]

Investor Relations Contact:

Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576
[email protected]

Media Relations Contact:

Tony Plohoros
6 Degrees
(908) 591-2839
[email protected]

LAS VEGAS, Dec. 01, 2020 (GLOBE NEWSWIRE) — The 4Less Group, Inc. (OTC: FLES) is pleased to announce today that stock research firm, Litchfield Hills Research LLC, released its initiation report rating the Company positively under its three-tiered (buy-hold-sell) rating system.

As of the end of its last trading day, FLES’s shares closed at $2.70 per share.

“We are pleased at the target price Litchfield Hills Research concluded on FLES. LiftKits4less.com is on track to have the best year ever, and I believe, this report further validates how big an opportunity a pure play marketplace for auto parts we are working to launch in early 2021 is,” said Timothy Armes, President of 4Less Group, Inc.

Litchfield Hills Research adheres to FINRA standards for quality and objectivity. The Litchfield Hills Research Department certifies its report is compliant with FINRA research rules 2241, 3110, the analyst is registered with FINRA, and the report has been reviewed by a Supervisory Analyst. Litchfield’s price target, financial models, peer comparisons, and investment thesis are developed without input from management of the company, and they run their own due diligence.

“As we continue to execute on launching our marketplace and began to announce and onboard re-sellers and auto parts manufacturers we are confident this will quickly translate into increased shareholder value as outlined in the report,” said Timothy.

The research report is MiFID II compliant and is classified as minor non-monetary benefit under MiFID II. It is accessible on Bloomberg, FactSet, NASDAQ, NYSE Connect, S&P Cap IQ, Thomson Reuters (Refinitiv) and 12 other platforms around the globe. It is posted to the research firm’s website http://www.hillsresearch.com/current-research/.

About The 4Less Group, Inc.:

With the acquisition of the URL AutoParts4Less.com, OTC: FLES is focusing all of their efforts and resources on building out and launching in early spring of 2021 a multi-vendor automotive parts marketplace (as opposed to reseller sites) with the potential to list and sell literally millions of parts that will include automotive specialty equipment parts and accessories, targeted “niche” web sites and potentially a used auto parts exchange as well.

Also visit: www.autoparts4Less.com as well as www.LiftKits4Less.com

CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including information about management’s view of the Company’s future expectations, plans and prospects. In particular, when used in the preceding discussion, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause results to differ include but are not limited to, successful performance of internal plans, product or services development and acceptance, the impact of competitive services and pricing, or general economic risks and uncertainties. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The Company takes no obligation to update or correct (i) its own forward-looking statements, except as required by law, or (ii) those prepared by third parties that are not paid for by the Company.

For more information, contact:

Email: [email protected]

Investor Relations:

Jon Stoddard
InvestorAcquisitionAdvisors.com
520-488-6704
[email protected]

WALTHAM, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) — Scipher Medicine, a precision immunology company matching patients with the most effective therapy, has appointed Mariann Byerwalter to its Board of Advisors. Byerwalter brings valuable insights into complex healthcare systems as the company launches its portfolio of molecular signature tests in the autoimmune market.

“Mariann’s broad healthcare expertise will add a valuable perspective to Scipher’s precision diagnostics, starting with PrismRA,” said Alif Saleh, Chief Executive Officer of Scipher Medicine. “It is an honor to have Mariann join Scipher as we bring precision medicine solutions to autoimmune disease.”

As the newest member of Scipher’s Board of Advisors, Byerwalter’s experience will provide Scipher with a unique viewpoint on how new precision medicine products and services fit into the larger healthcare ecosystem in order to drive patient access and adoption.

“I look forward to working with Scipher as they bring this new technology to underserved areas of healthcare,” said Mariann Byerwalter. “Precision solutions promise to improve both patient outcomes and health system efficiency.”

Byerwalter is Chairman Emeritus of the SRI International. She serves on the Stanford Health Care Board of Directors, where she was Chairman of the Board of Directors from 2006 through 2013, and served as the Interim President and CEO of Stanford Health Care in 2016. Byerwalter also sits on the Board of Directors of Pacific Life, Franklin Resources, and Lucile Packard Children’s Hospital. She holds a B.A. degree from Stanford University and an MBA from Harvard Business School.

Byerwalter joins Dr. Regina Benjamin, 18th Surgeon General of the United States, on Scipher’s Board of Advisors.

About PrismRA® 

PrismRA, a molecular signature test, is a revolutionary advancement bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally. From a routine blood draw, the PrismRA test analyzes an individual’s molecular signature, helping identify who is unlikely to adequately respond to TNFi therapy, the world’s largest selling drug class, so non-responders can be prescribed alternative effective therapy. Providers now have objective data to guide therapeutic decision-making and give patients the best chance of achieving treatment targets and improving clinical outcomes. For more information, please visit www.PrismRA.com.

About Scipher Medicine

Scipher Medicine holds the fundamental belief that patients deserve simple answers to treatment options based on scientifically backed data. Leveraging our proprietary Network Medicine platform and artificial intelligence, we commercialize blood tests revealing a persons’ unique molecular disease signature and match such signature to the most effective therapy, ensuring optimal treatment from day one. The unprecedented amount of patient molecular data generated from our tests further drives the discovery and development of novel and more effective therapeutics. We partner with payers, providers, and pharma along the health care value chain to bring precision medicine to autoimmune diseases. Visit www.sciphermedicine.com and follow Scipher on Twitter, Facebook, and LinkedIn. 

Media Contact:

Alexander Petti
[email protected]
201-978-4882

Scipher Medicine company contact: 
Lauren Kendall
[email protected]
520-400-5346

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/46d2020c-fa71-4655-a7c0-051803c8498c

BASKING RIDGE, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that its gammaCore non-invasive vagus nerve stimulator (nVNS) has been selected for evaluation in a randomized controlled study for the treatment of opioid use disorders. The study is being run by Dr. Douglas Bremner at Emory University in collaboration with the Georgia Institute of Technology and the City University of New York and is supported by the National Institute on Drug Abuse (NCT04556552).

The study will enroll 40 subjects, in two separate study groups of 20 subjects each. Each study group will randomize 10 subjects to be treated with nVNS and 10 with sham stimulation. The study will assess the ability of nVNS to decrease opioid cravings in subjects with a history of opioid use disorder who are stable on medication, as well as examine the possible mechanisms that might facilitate this clinical effect.

Dr. Douglas Bremner, Professor of Psychiatry and Behavioral Sciences and Radiology at the Emory University School of Medicine, staff physician at the Atlanta Veterans Clinic General Mental Health Unit at the Atlanta VA Medical Center and primary investigator of the study, commented: “Opioid use disorders (OUDs) are highly prevalent and potentially lethal conditions that are often linked to trauma and post-traumatic stress disorder. These conditions are of particular concern to the VA and limited treatment options currently exist. The use of nVNS during the opioid withdrawal period represents a potential new innovation versus current treatments that rely on medication and counseling, widely acknowledged to have limitations during this critical period. Novel treatments are needed that address the underlying neurobiology of OUDs involving the sympathetic nervous system, inflammatory responses, and brain areas and systems mediating craving and addiction. nVNS has previously been shown to be effective in treating a number of conditions, including most forms of primary headache, depression and epilepsy, and has also been shown to affect the underlying neurobiology of OUDs.”

Peter Staats, MD, MBA, Chief Medical Officer of electroCore and President-elect of the World Institute of Pain, stated: “Addiction is a significant health crisis in the United States. Data suggests that nVNS may play a meaningful role in the treatment of addiction by ameliorating the devastating cravings associated with opioids and opioid withdrawal. With the introduction of our effective, safe and practical handheld treatment in the form of gammaCore (nVNS), we are now in a position to fully investigate the clinical potential of nVNS in this important area. This has not been possible with vagus nerve stimulation generated through surgically implanted devices. The Health and Human Services’ Best Practices for Pain Management Task Force already highlights nVNS as an alternative to opioids for patients suffering from cluster and migraine headache, and Dr. Bremner’s work suggests that nVNS may have a much broader role in the treatment of patients with addiction and withdrawal as well.  We all look forward to results of this important study.”

The study will enroll subjects with confirmed OUDs based on DSM-5 criteria from the greater Atlanta metropolitan region. According to the Substance Abuse and Mental Health Services Administration (SAMHSA), over 100,000 people in the Atlanta area engage in non-medical use of prescription pain relievers, and almost half of them are estimated to have an opioid use disorder. The study will recruit from treatment programs in the greater Atlanta metropolitan region, including the residential, detoxification and other treatment programs of the DeKalb Community Service Board, which, with over 30,000 patient visits per year, represents the largest treatment program for OUDs in one of two counties in greater Atlanta.

For more information on the Health and Human Services’ Pain Management Best Practices Inter-Agency Task Force Report please visit: https://www.hhs.gov/sites/default/files/pmtf-final-report-2019-05-23.pdf

About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About gammaCore™

gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. 

gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

• Safety and efficacy of gammaCore have not been evaluated in the following patients:
  • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
  • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
  • Pediatric patients
  • Pregnant women
  • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
• Patients should not use gammaCore if they:
  • Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
  • Have a metallic device such as a stent, bone plate, or bone screw implanted at or near their neck
  • Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

In the US, the FDA has not cleared gammaCore for the treatment of pneumonia and/or respiratory disorders such as acute respiratory stress disorder associated with COVID-19.

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

gammaCore Sapphire™ CV has received Emergency Use Authorization (EUA) from the FDA for acute use at home or in a healthcare setting to treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider, by using non-invasive Vagus Nerve Stimulation (nVNS) on either side of the patient’s neck during the Coronavirus Disease 2019 (COVID-19) pandemic.

gammaCore Sapphire CV has neither been cleared nor approved for acute use at home or in a healthcare setting to treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider, by using non-invasive Vagus nerve Stimulation (nVNS) on either side of the patient’s neck during the Coronavirus Disease 2019 (COVID-19) pandemic

gammaCore Sapphire CV has been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked.

Please refer to gammaCore Sapphire CV (nVNS) Instructions for Use for Use for all of the important warnings and precautions before using or prescribing gammaCore Sapphire CV (nVNS).

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the business, operating or financial impact of such studies; the potential of nVNS generally and gammaCore in particular to treat opioid use disorders and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.

Investors:

Hans Vitzthum
LifeSci Advisors
617-430-7578
[email protected]

or

Media Contact:

Jackie Dorsky
electroCore
973-290-0097
[email protected]

GUELPH, Ontario, Dec. 01, 2020 (GLOBE NEWSWIRE) — Quick Service Restaurant (QSR) chains across Canada are going digital at the drive-thru with the help of Melitron Corporation and Samsung Electronics Canada. Melitron, a Guelph-based manufacturer of integrated metal enclosure systems for technology products, partnered with Samsung Canada in 2017 to design and manufacture weatherproof, highly durable outdoor digital menu board and signage systems with fully integrated Samsung displays for one of the first large scale quick service restaurant chains in Canada to adopt digital at the drive-thru. Today, Melitron-manufactured outdoor digital menu boards and outdoor digital signage can be found at most of the top quick service restaurant chains across Canada.

“Samsung OHF series display technology with its extreme temperature tolerance and high visibility even in direct sunlight was first introduced to the market in 2016, presenting us with the opportunity to manufacture commercial grade digital signage and kiosks built for the outdoors,” said Mike Turner, President and CEO at Melitron. “Today, over 10,000 Samsung OHF series displays are lighting up drive-thrus across Canada in Melitron-manufactured outdoor digital menu boards and digital signage. Thousands more are planned for rollout through 2021.”

“Melitron has integrated Samsung’s innovative OHF series display technology into well-designed, highly durable outdoor digital menu boards and digital signage solutions,” said Mary Peterson, Vice President, IT & Enterprise Solutions, Samsung Canada. “Their in-house-manufacturing approach ensures a superior quality product, reliable production schedules, and well-executed rollout complete with fast and efficient on-site installation and setup. The speed of development, manufacturing and deployment combined with their commitment to quality and service excellence has been impressive, making them an ideal business partner for Samsung Canada and leading quick service restaurant clients.”

Prior to the COVID-19 pandemic, up to 70 per cent of restaurant revenues came from drive-thru orders, making a clear case for quick service restaurants to invest in digital technology. The digital approach has shown to increase sales by promoting the right products at the right time through automatic menu changes based on time of day, such as from breakfast to lunch to dinner, and according to the weather, like advertising ice cream during hot weather, for example.

Digital at the drive-thru has become even more essential to restaurant revenues during the COVID-19 pandemic as dining areas closed and order sizes at the drive-thru increased.

Looking ahead, quick service restaurants that have made the switch to digital are well positioned to quickly adopt new levels of service at the drive-thru, such as customized menus and promotions based on each unique visitor.

For more information about Melitron Outdoor Digital Signage and Kiosk Solutions, visit www.melitron.com/digital-signage. For more information on Samsung Digital Display solutions, visit Samsung.com/ca/business.

About Melitron

Melitron is a leading designer, manufacturer and contract manufacturing services provider of durable metal enclosures and electro-mechanical systems for electronics and electrical products with a focus on smart design, superior quality and exceptional service. The Company also offers a Melitron-branded, fully customizable line of indoor and outdoor digital signage and kiosk solutions, including outdoor digital menu boards, featuring leading electronics brands. The Company’s contract manufacturing services take projects and new product introductions from concept to design and prototyping through to production manufacturing, finishing, electro-mechanical systems integration, delivery and installation. The Company’s world class facilities feature the most advanced technologies in manufacturing, robotics and automation, and are certified to meet the stringent standards of regulatory requirements across industries. Established in 1995, Melitron Corporation is a privately-held Canadian company located in Guelph, Ontario, which is situated along the corridor between Toronto and Waterloo Region in Southwestern Ontario, Canada’s most populous region. For more information, visit www.melitron.com.

About Samsung Electronics Canada Inc.

Samsung Electronics Canada inspires Canadians to reach their full potential through a transformative ecosystem of products and services that deliver innovation and distinct design to every aspect of their connected lives. The company is redefining the worlds of TVs, smartphones, virtual reality and wearable devices, tablets and digital appliances. In 2020, Samsung was ranked as one of Canada’s “Most Admired Brands” in Leger’s Corporate Reputation Study.” “Best Global Brands” list. Dedicated to helping make a difference in the lives of Canadians, Samsung’s award-winning corporate giving initiatives support public education and health-related issues in communities across the country. To discover more, please visit www.samsung.com.

Follow Samsung Canada at facebook.com/SamsungCanada, or Instagram @samsungcanada or Twitter @SamsungCanada.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/25605153-5dab-48dd-97e0-70c5b29495a3.

Media Contact:

Melitron
[email protected]

Chris Dionne
North Strategic (for Samsung Canada)
[email protected]
416-500-3802

New Platform Leverages the Internet of Things (IoT), 3D Mapping and Gamification to Make Returning to Work Safe and Engaging for Employees

CALABASAS, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK) (“NETSOL” or the “Company”) a global services and enterprise application solutions provider, in collaboration with WRLD, an immersive 3D mapping technology company, today introduced NXT, a COVID-aware smart workplace solution.

NXT enables employees to safely return to the office by ensuring standard operating procedures are enforced and offering seamless communication and virtual interaction for those continuing to work remotely. The NXT platform, powered by WRLD, leverages IoT technology and 3D gaming quality maps to connect and engage employees with their workplace while also ensuring they follow strict COVID-safety protocols such as contact tracing, wellness checks and social distancing while in the office. The NXT platform has been successfully put into practice at NETSOL offices and is available as a software application that can be quickly scaled for companies of all sizes. To view a video showcasing the NXT workplace platform key features, please visit: https://netsoltech.com/nxt/

“The global pandemic has radically transformed the modern working environment and has made even more clear every company’s responsibility to their employees’ health and safety,” said Faisal Bhatti, NETSOL’s Global Human Capital Management Officer. “Our collaboration with WRLD to transition our global operations to a work-from-home hybridization helped to inform the NXT product. We believe its applications will be beneficial to any organization looking to meet today’s unique challenges both during and post-pandemic. NXT has enabled our company to establish and enforce robust standard operating procedures (SOPs) to bring employees back to work in an efficient and socially distant manner, while simultaneously keeping in contact with employees’ productivity on and off-campus.”

The NXT workplace is a flexible platform that interfaces with an organization’s HR and building management as well as its IoT, productivity and wellness systems to create a Digital Twin of its office space and provide real-time workplace intelligence. Through IoT datasets such as indoor positioning and occupancy sensors, NXT helps employees to assign workspaces and book meetings in real-time while socially distancing within the office. The NXT platform has been optimized to provide organizations with administrative control over protected data, establishing a fully-secure and cloud-integrated system that enables remote access and on-prem management. The NXT platform features include:

• 3D real-time “Digital Twin” of office space.
• Real-time COVID-radius display, ensuring six-foot distances are being maintained.
• Integration and visualization with IoT sensors for occupancy and footfall management, temperature, air quality, and sensors.
• Building and work-from-home (WFH) check-in capabilities via mobile app.
• Virtual reality/augmented reality (VR/AR) telepresence capabilities.
• Online meeting room booking, workspace allocation and safe distance occupancy management.
• Employee health and wellness SOP and temperature check-ins.
• Real-time productivity management systems: GitHub, JIRA, Microsoft Teams.
• Turn-by-turn mapping for navigation and interior wayfinding.
• Security systems and real-time video feed of office space.
• Fault reporting and customer service management.

“Our initial implementations at NETSOL’s headquarters and at a leading financial and media company headquartered in New York have allowed us to prove out our technology as well as establish market readiness for our state-of-the-art platform, NXT,” said Iain Bethune Head of Software Development at WRLD. “We look forward to continuing our work with NETSOL to help other companies bring their employees back to the office and assure them it can be done safely and efficiently.”

The NXT platform leverages WRLD’s rapid indoor map creation capabilities that allow the NXT workplace to be implemented in 30 days with full customer-specific integrations, deployment, and installation within just 60 days. WRLD has implemented a flexible pricing model based for NXT either on square footage per year or monthly active users, offering entry-level pricing for SMEs as well.

To learn more about the NXT workplace application please visit here.

About NETSOL Technologies

NETSOL Technologies, Inc. (Nasdaq: NTWK) is a worldwide provider of IT and enterprise software solutions primarily serving the global leasing and finance industry. The Company’s suite of applications is backed by 40 years of domain expertise and supported by a committed team of more than 1300 professionals placed in eight strategically located support and delivery centers throughout the world. NFS, LeasePak, LeaseSoft or NFS Ascent – help companies transform their Finance and Leasing operations, providing a fully automated asset-based finance solution covering the complete finance and leasing lifecycle.

About WRLD

The WRLD platform provides users with all the tools and services they need to build interactive, location-aware experiences for web, mobile, and virtual reality/augmented reality (VR/AR). With custom built map design tools and cross-platform software development kits (SDKs), users can create beautiful, responsive and engaging apps. WRLD can help users visualize data in a completely unique way to not only interact with it but also acquire business value.

WRLD’s Digital Twins create a bridge between digital and physical worlds. The company has delivered and operationalized immersive experiences for some of the most storied Fortune 500 enterprises. WRLD 3D maps are built using high-quality geographic data so companies can create 3D visualizations, run simulations, and develop dynamic, location-based experiences and games. WRLD offers robust digital map-making power for developers to quickly create virtual worlds, smart buildings and more.

Forward-Looking Statements

This press release may contain forward-looking statements relating to the development of the Company’s products and services and future operating results, including statements regarding the Company that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words “expects,” “anticipates,” variations of such words, and similar expressions identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Factors that could affect the Company’s actual results include the progress and costs of the development of products and services and the timing of the market acceptance. The subject Companies expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

Investor Relations Contact:

Matt Glover and Tom Colton

Gateway Investor Relations
1-949-574-3860
[email protected]

Media Relations Contact:

Kathryn Kelly
Kelly Communications
[email protected]

WASHINGTON and ARLINGTON, Va. and SCHAUMBURG, Ill. and OTTAWA, Dec. 01, 2020 (GLOBE NEWSWIRE) — With climate risk issues receiving increased focus in 2020 and poised for even greater attention from the public and public policymakers in 2021, the Actuaries Climate Index continues to provide important up-to-date data for discussions on climate policy.

“The Actuaries Climate Index’s presentation of changes in key climate conditions across the United States and Canada is transparent, objective, and scientifically grounded—an ideal source for those engaging in discussions about climate-related policies,” says Doug Collins, chair of the Climate Index Working Group.

The key metric in the Actuaries Climate Index of a seasonal five-year moving average presents a composite measure of long-term changes across an array of observed weather extremes and sea levels in the two countries. It has steadily climbed from its most recent low of 0.70 in 2015 to a new high of 1.19 for the moving average in spring 2020. The measurements of extreme climate conditions tracked by the index—high and low temperatures, heavy rain, drought, high wind, and sea level—continue to move away from zero, which was the baseline for the index reference period of 1961 to 1990. The spring 2020 data release incorporates newly available sea level data for Canada for 2019.

A chart accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4629c76b-bae7-477c-9bef-cf9e5d8455e8

The Actuaries Climate Index is based on an analysis of seasonal data from neutral, scientific sources for six index components collected since 1961. The index measures changes in these components for the United States and Canada combined and by region. Combining six components over a five-year measurement period, the index’s moving average smooths out monthly and seasonal fluctuations for a meaningful measurement of long-term climate trends.

The index—sponsored by the American Academy of Actuaries, the Canadian Institute of Actuaries, the Casualty Actuarial Society, and the Society of Actuaries—is designed to provide actuaries, public policymakers, and the general public with objective data about changes in the frequency of extreme climate conditions over recent decades.

Updated values are posted quarterly on ActuariesClimateIndex.org as data for each meteorological season become available.

About the Sponsoring Organizations

The American Academy of Actuaries is a 19,500-member professional association whose mission is to serve the public and the U.S. actuarial profession. For more than 50 years, the Academy has assisted public policymakers on all levels by providing leadership, objective expertise, and actuarial advice on risk and financial security issues. The Academy also sets qualification, practice, and professionalism standards for actuaries in the United States.

The Canadian Institute of Actuaries (CIA) is the national, bilingual organization and voice of the actuarial profession in Canada. Our more than 6,000 members are dedicated to providing actuarial services and advice of the highest quality. The Institute holds the duty of the profession to the public above the needs of the profession and its members.

The Casualty Actuarial Society (CAS) is a leading international organization for credentialing and professional education. Founded in 1914, the CAS is the world’s only actuarial organization focused exclusively on property and casualty risks and serves over 9,000 members worldwide. Professionals educated by the CAS empower business and government to make well-informed strategic, financial and operational decisions.

With roots dating back to 1889, the Society of Actuaries (SOA) is the world’s largest actuarial professional organization with more than 31,000 actuaries as members. Through research and education, the SOA’s mission is to advance actuarial knowledge and to enhance the ability of actuaries to provide expert advice and relevant solutions for financial, business and societal challenges. The SOA’s vision is for actuaries to be the leading professionals in the measurement and management of risk.

Media contact
Sandra Caya
Director, Communications and Public Affairs, Canadian Institute of Actuaries
[email protected]
613-236-8196 ext. 116

 

VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) — Clarity Gold Corp. (“Clarity” or the “Company”) (CSE: CLAR, OTC: CLGCF, FSE: 27G) is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”). DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that manages the electronic clearing and settlement of publicly traded companies in the United States.

Clarity’s common shares are now fully DTC eligible and will continue to trade under the ticker symbol “CLGCF” on the OTC Markets. Through an electronic method of clearing securities, DTC eligibility simplifies the process of trading and transferring the Company’s common shares between brokerages in the United States.

“Clarity’s DTC eligibility is a crucial step for us and our shareholders” says James Rogers, CEO of Clarity Gold Corp. “We are actively engaged in pursuing new avenues to broaden the reach of our story; receiving DTC eligibility can help increase liquidity, cut costs and enable the stock to be traded over a broader network of potential investors. Our common shares are now more widely accessible to United States investors, both retail and institutional. We are excited to introduce Clarity to one of the largest markets in the world” continued Mr. Rogers.

The Company also announces it has retained Greentimes Consulting Ltd. (“Greentimes”) for total cash consideration for EU325,000 for a 6-month term. Greentimes has been engaged to create and implement an international digital marketing and awareness campaign including providing native advertising and digital marketing services for the Company.

About Clarity

Clarity Gold Corp. is a Canadian mineral exploration company focused on the acquisition, exploration and development of gold projects in Canada. The Company has entered into an option agreement to purchase 100% of the Destiny Project, a 5,013 ha gold-focused project in the mineral rich Abitibi region in Quebec. Clarity is also working on the exploration of its 10,518 ha Empirical Project located approximately 12 km south of Lillooet, BC, and has recently expanded its mineral property portfolio with the acquisitions of the Tyber and Gretna Green projects, both located on Vancouver Island, British Columbia. The Company is based in Vancouver, British Columbia, and is listed on the CSE under the symbol “CLAR”. To learn more about Clarity Gold Corp. and its projects please visit www.claritygoldcorp.com.

ON BEHALF OF THE BOARD

“James Rogers”
Chief Executive Officer
Tel: 1 (833) 387-7436
Email: [email protected]
Website: claritygoldcorp.com

FORWARD-LOOKING STATEMETNS

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities,
events
or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding: the Transaction and the terms thereof; that the acquisition of the Destiny Project will mark a transformational first step for the Company into the Abitibi Greenstone belt; that the Company will enter into the definitive agreement; that the Company will complete the Offering; that the Company will obtain the necessary regulatory and other approvals required to close the Transaction; and the intended use of the proceeds of the Offering. The forward-looking statements reflect management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements
including: that the applicable stock exchanges may not approve the Transaction as proposed or at all; that the parties may not enter into a definitive agreement in connection with the Transaction; that the parties may not be able to satisfy the conditions to closing of the Transaction; the inability of the Company to complete the Offering at all or on the terms announced; adverse market conditions; and other factors beyond the control of the parties.
Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not
guarantees
of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether
as a result of
new information, future events or otherwise, except as required by applicable law.

The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.